Diltiazem used as a tacrolimus-sparing agent for treatment of pediatric patients with refractory nephrotic syndrome: a case report and retrospective analysis
- 68 Downloads
A 5-year-old boy was referred to our hospital in March 2017 (day 0) because he had continued to suffer from vomiting, abdominal pain, and systemic edema since a month ago. The laboratory results exhibited a large number of urinary proteins (24-h urine protein, 4.51 g/L), hypoalbuminemia (albumin, 14.6 g/L), hypercholesterolemia (total cholesterol, 8.06 mmol/L), and systemic edema. This patient had no food or drug allergic history. He was initially diagnosed with nephrotic syndrome and received a standard amount of oral corticosteroids (prednisone 40 mg qd) for 4-week period therapy. After 18-day medication (day 18), however, there was still a large amount of protein in his urine. He was hospitalized. On April 5 (day 28), renal biopsy results indicated this boy was with IgM nephropathy. Other relevant laboratory tests...
J.Y. Sun, Y.H. Hu, and H.L. Guo measured blood tacrolimus concentrations and detected the CYP3A5 genotype. Z.J. Xu, X. Jing, F. Sun, and X.S. Ding involved in counseling on drug therapy. H.L. Guo was responsible for the patients. J.Y. Sun, H.L. Guo, and F. Chen analyzed the data and wrote the manuscript. J. Xu critically revised the manuscript.
This work was supported by the Hospital Pharmacy Foundation of Jiangsu Pharmaceutical Association (A201606 and 2016YX011).
Compliance with ethical standards
The ethical approval was provided by the IEC of Children’s Hospital Affiliated to Nanjing Medical University. The informed consent was obtained from the children’s parents.
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ, Leeder JS, van Schaik R, Thummel KE, Klein TE, Caudle KE, MacPhee IA (2015) Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther 98(1):19–24. https://doi.org/10.1002/cpt.113 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Hardy G, Stanke-Labesque F, Contamin C, Serre-Debeauvais F, Bayle F, Zaoui P, Bessard G (2004) Protease inhibitors and diltiazem increase tacrolimus blood concentration in a patient with renal transplantation: a case report. Eur J Clin Pharmacol 60(8):603–605. https://doi.org/10.1007/s00228-004-0824-2 CrossRefPubMedGoogle Scholar
- 11.Li JL, Wang XD, Chen SY, Liu LS, Fu Q, Chen X, Teng LC, Wang CX, Huang M (2011) Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. Pharmacogenomics J 11(4):300–306. https://doi.org/10.1038/tpj.2010.42 CrossRefPubMedGoogle Scholar